Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Chinese (SSE) Clinical Research and Equipment Industry Analysis

UpdatedJul 01, 2026
DataAggregated Company Financials
Companies27
  • 7D13.6%
  • 3M7.7%
  • 1Y40.6%
  • YTDn/a

In the last week, the Clinical Research and Equipment industry is up 15%, with WuXi AppTec up 17%. During this same period, the Shanghai Runda Medical Technology underperformed, falling 15%. This means that the industry has gained 45% over the past year. Earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Jul 2026CN¥649.0bCN¥98.8bCN¥21.9b61.9x29.7x6.6x
Fri, 29 May 2026CN¥560.6bCN¥98.7bCN¥21.7b54x25.8x5.7x
Sun, 26 Apr 2026CN¥586.6bCN¥95.3bCN¥20.9b60.7x28.1x6.2x
Tue, 24 Mar 2026CN¥504.3bCN¥94.5bCN¥18.7b53.7x27x5.3x
Thu, 19 Feb 2026CN¥608.6bCN¥94.4bCN¥18.6b68.1x32.8x6.5x
Sat, 17 Jan 2026CN¥634.2bCN¥94.3bCN¥18.5b65.2x34.2x6.7x
Mon, 15 Dec 2025CN¥564.3bCN¥94.3bCN¥18.5b63.6x30.5x6x
Wed, 12 Nov 2025CN¥566.0bCN¥94.3bCN¥18.5b67.3x30.5x6x
Fri, 10 Oct 2025CN¥639.0bCN¥92.1bCN¥17.4b69.1x36.6x6.9x
Sun, 07 Sep 2025CN¥623.6bCN¥92.3bCN¥17.5b58.6x35.6x6.8x
Tue, 05 Aug 2025CN¥565.1bCN¥91.6bCN¥17.9b59.2x31.6x6.2x
Thu, 03 Jul 2025CN¥446.7bCN¥89.8bCN¥15.4b48.7x29.1x5x
Sat, 31 May 2025CN¥412.6bCN¥89.1bCN¥15.3b45.6x27x4.6x
Mon, 28 Apr 2025CN¥379.9bCN¥87.6bCN¥13.5b39.3x28.2x4.3x
Wed, 26 Mar 2025CN¥432.8bCN¥88.4bCN¥14.6b41.7x29.7x4.9x
Fri, 21 Feb 2025CN¥436.5bCN¥88.1bCN¥11.2b49x38.8x5x
Sun, 19 Jan 2025CN¥351.9bCN¥88.1bCN¥11.2b37x31.3x4x
Tue, 17 Dec 2024CN¥386.4bCN¥87.8bCN¥11.2b39.7x34.5x4.4x
Thu, 14 Nov 2024CN¥403.3bCN¥87.8bCN¥11.2b43.2x36.1x4.6x
Sat, 12 Oct 2024CN¥364.2bCN¥88.2bCN¥12.4b34.3x29.4x4.1x
Mon, 09 Sep 2024CN¥274.1bCN¥87.1bCN¥12.3b27.9x22.3x3.1x
Wed, 07 Aug 2024CN¥307.0bCN¥87.6bCN¥12.6b29.3x24.4x3.5x
Fri, 05 Jul 2024CN¥267.1bCN¥88.3bCN¥13.4b23.7x19.9x3x
Sun, 02 Jun 2024CN¥309.0bCN¥88.3bCN¥13.4b27.5x23.1x3.5x
Tue, 30 Apr 2024CN¥331.7bCN¥90.2bCN¥14.4b30.8x23x3.7x
Thu, 28 Mar 2024CN¥334.3bCN¥90.4bCN¥15.6b31.5x21.4x3.7x
Sat, 24 Feb 2024CN¥358.9bCN¥91.1bCN¥16.1b32.3x22.3x3.9x
Mon, 22 Jan 2024CN¥452.0bCN¥91.1bCN¥16.1b35.4x28.1x5x
Wed, 20 Dec 2023CN¥472.9bCN¥91.1bCN¥16.1b37.2x29.4x5.2x
Fri, 17 Nov 2023CN¥558.3bCN¥91.1bCN¥16.1b39x34.7x6.1x
Sun, 15 Oct 2023CN¥548.6bCN¥92.0bCN¥18.3b36.2x29.9x6x
Tue, 12 Sep 2023CN¥478.5bCN¥91.9bCN¥18.3b33.2x26.1x5.2x
Thu, 10 Aug 2023CN¥500.7bCN¥91.8bCN¥18.5b35.9x27.1x5.5x
Sat, 08 Jul 2023CN¥447.2bCN¥91.3bCN¥18.5b34.1x24.2x4.9x
Price to Earnings Ratio

24.2x


Total Market Cap: CN¥447.2bTotal Earnings: CN¥18.5bTotal Revenue: CN¥91.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Chinese Clinical Research and Equipment Industry Price to Earnings3Y Average 28.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Chinese Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 28.7x.
  • The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 6.6x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 5.8% per year over the last three years.
  • Revenues for these companies have grown 2.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Chinese Clinical Research and Equipment compare with similar industries?

CN Market0.67%
Healthcare0.75%
Life Sciences13.62%
Clinical Research and Equipment13.62%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
603259 WuXi AppTecCN¥125.208.5%
+CN¥29.1b		78.3%PE19.8x
300759 Pharmaron BeijingCN¥29.9720.8%
+CN¥9.4b		22.3%PE32.4x
300347 Hangzhou Tigermed ConsultingCN¥47.489.5%
+CN¥3.5b		-11.7%PE52.6x
603127 Joinn Laboratories(China)Co.LtdCN¥40.947.5%
+CN¥2.1b		86.5%PE60.6x
688202 Shanghai MedicilonCN¥82.3122.3%
+CN¥2.0b		130.9%PS8.6x

Latest News

688758
CN¥22.88
Suzhou Sepax Technologies
7D
16.4%
1Y
36.8%
300347
CN¥47.48
Hangzhou Tigermed Consulting
7D
9.5%
1Y
-11.7%
300030
CN¥6.14
Improve Medical Instruments
7D
-1.9%
1Y
-22.0%
300759
CN¥29.97
Pharmaron Beijing
7D
20.8%
1Y
22.3%
300463
CN¥8.50
Maccura BiotechnologyLtd
7D
-0.8%
1Y
-28.5%
603127
CN¥40.94
Joinn Laboratories(China)Co.Ltd
7D
7.5%
1Y
86.5%
688068
CN¥93.00
Beijing Hotgen Biotech
7D
15.7%
1Y
-36.8%
688755
CN¥28.11
Jiangsu Hanbon Science and Technology
7D
-4.5%
1Y
-20.2%
603108
CN¥9.38
Shanghai Runda Medical Technology
7D
-6.2%
1Y
-45.9%
688202
CN¥82.31
Shanghai Medicilon
7D
22.3%
1Y
130.9%
688046
CN¥25.77
GemPharmatech
7D
21.7%
1Y
73.9%
603259
CN¥125.20
WuXi AppTec
7D
8.5%
1Y
78.3%
Narrative Update • Jun 29

603259: APAC Conviction List Inclusion Will Support Upside From Ongoing Share Buybacks

Analysts have raised their fair value estimate for WuXi AppTec from CN¥137.83 to CN¥145.96, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that are reflected in recent research, including its addition to a major APAC conviction list. What's in the News for WuXi AppTec WuXi AppTec's Board of Directors authorized a new share buyback plan on June 9, 2026, signaling continued use of repurchases as a capital management tool.